Not yet recruiting NCT06699368

Clinical Study on the Risk of Left Atrial POP Ablation and Esophageal Injury Under Ultra-High Power and Related Influencing Parameters

No phase Interventional Ultra-High Power Ablation,Safety of Atrial Fibrillation Ablation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: The ultra-high-power ablation group, The high-power ablation group.
Who it may be relevant to: Registry conditions: Ultra-High Power Ablation,Safety of Atrial Fibrillation Ablation. Basic parameters: 18 years — 85 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Center list to be confirmed — check the primary protocol.
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study aims to evaluate the risks of steam pop (POP) and esophageal injury, as well as related influencing parameters, under ultra-high power ablation technology. In the treatment of arrhythmias such as atrial fibrillation, cardiac ablation surgery is a common method. The use of ultra-high power ablation technology can shorten the operation time and improve effectiveness, but it may also increase the risk of damage to surrounding structures such as the esophagus. We will recruit a certain number of patients who are scheduled to undergo ultra-high power ablation surgery. We will record various parameters during the surgery, such as energy, time, and contact force, and monitor patients for signs of esophageal injury after the surgery. We expect that through this study, we can better understand the potential risks of ultra-high power ablation to the esophagus and identify the key parameters affecting these risks. This will help to improve surgical techniques, reduce complications, and enhance patient safety and surgical outcomes.

Detailed description

Interventions

Procedure The ultra-high-power ablation group
The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
Procedure The high-power ablation group
The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.

Primary outcome measures

The number of times the esophageal temperature monitoring electrode shows a temperature exceeding 38.5°C [Time frame: Intraoperative Immediate]

Secondary outcome measures (1)

The number of times Intraoperative steam POP occurrence [Time frame: Intraoperative Immediate]

Eligibility criteria

Inclusion criteria

Patients aged between 18 and 80 years old.
Diagnosed with drug-refractory, symptomatic, paroxysmal atrial fibrillation.
Non-valvular atrial fibrillation.
Able to understand the purpose of the study, voluntarily participate in this research, and the patient or their legal representative signs the informed consent form, willing to complete follow-ups as required by the protocol.

Exclusion criteria

Atrial fibrillation secondary to thyroid disease or other reversible factors;
Imaging studies indicating intracardiac thrombus;
Moderate to severe mitral stenosis or regurgitation;
Left ventricular ejection fraction <40%, or New York Heart Association (NYHA) functional class III or IV;
Unstable angina;
Myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months prior to enrollment;
Presence of mural thrombus, space-occupying disease, or other abnormalities that hinder vascular puncture or catheter manipulation;
Contraindications to anticoagulation and a history of blood coagulation or bleeding abnormalities;
Patients with active systemic infections; Patients who have had an atrial septal closure device implanted within the last 6 weeks;
Female patients who are pregnant, breastfeeding, or unable to use contraception during the study period;
Patients with a life expectancy of less than 12 months (e.g., advanced malignant tumors); patients who have had an atrial septal closure device implanted within the last 6 weeks;
Conditions affecting vascular access;
Patients who are concurrently participating in other drug or device clinical trials;
Any other abnormalities or diseases that the investigator deems should exclude the patient from the study enrollment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: Randomized
Model: Parallel assignment
Masking: Single blind
Primary purpose: Prevention

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06699368 · CDSY-UHP-POP-ESO

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗